OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(20)
Publication Date
Release Date
2025
(4)
2024
(3)
2023
(3)
2020
(3)
2021
(2)
2017
(2)
2019
(1)
2015
(1)
2013
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists.
Not available
S-EPMC12138406
|
biostudies-literature
Cite
Absolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer.
Not available
S-EPMC3530689
|
biostudies-literature
Cite
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Not available
S-EPMC11333275
|
biostudies-literature
Cite
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
Not available
S-EPMC7528620
|
biostudies-literature
Cite
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Not available
S-EPMC12583187
|
biostudies-literature
Cite
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
Not available
S-EPMC4830270
|
biostudies-literature
Cite
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Not available
S-EPMC12464853
|
biostudies-literature
Cite
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Not available
S-EPMC10275699
|
biostudies-literature
Cite
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
Not available
S-EPMC12684762
|
biostudies-literature
Cite
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Not available
S-EPMC10463194
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets